Form 8-K - Current report:
SEC Accession No. 0001171843-23-002089
Filing Date
2023-04-03
Accepted
2023-04-03 16:10:48
Documents
12
Period of Report
2023-03-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_040323.htm   iXBRL 8-K 24433
  Complete submission text file 0001171843-23-002089.txt   195880

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE crvs-20230329.xsd EX-101.SCH 2935
3 XBRL LABEL FILE crvs-20230329_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE crvs-20230329_pre.xml EX-101.PRE 22343
6 EXTRACTED XBRL INSTANCE DOCUMENT f8k_040323_htm.xml XML 3610
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

EIN.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37719 | Film No.: 23792715
SIC: 2834 Pharmaceutical Preparations